Systemic absorption of rifamycin SV MMX administered as modified-release tablets in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 2122-2128

  Di Stefano, A F D ^a   Rusca, A ^a   Loprete, L ^a   Droge M J ^b   Moro, L ^c   Assandri, A ^a  

^a Cross Research SA   (Switzerland)

^b Analytisch Biochemisch Laboratorium BV (ABL)   (Netherlands)

^c Cosmo Technologies Ltd ^*  (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMYCIN; RIFAMYCIN SV DERIVATIVE;

ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; COLON; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG RELEASE; DRUG URINE LEVEL; ELECTROCARDIOGRAM; FEMALE; HUMAN; INTESTINE ABSORPTION; MALE; MULTIPLE DRUG DOSE; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TABLET; URINARY EXCRETION; VITAL SIGN; VOLUNTEER;

ADULT; AGED; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; RIFAMYCINS; TABLETS;

EID: 79955530753     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01504-10     Document Type: Article

References (24)

1. Acocella, G., G. C. Baroni, and R. Muschio. 1962. Comparative study, in normal subjects and liver disease patients, of the absorption and elimination of rifomycin SV administered in a single oral or intramuscular dose. G. Mal. Infett. Parassit. 14:548-551. [In Italian.]
2. Adachi, J. A., and H. L. DuPont. 2006. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin. Infect. Dis. 42:541-547.
3. Alfa Wassermann S.p.A. 2000. Summary of product characteristics of Normix®; last revision, June 2000. Alfa Wassermann S.p.A., Alanno, Italy.
4. Assandri, A., A. Perazzi, and M. Berti. 1977. Studies of binding C3-substitute rifamycins to human and bovine serum albumin. J. Antibiot. 30:409-415. (Pubitemid 8113113)
5. Bergamini, N., and G. G. Fowst. 1965. Rifamycin SV: a review. Arzneimittelforschung 15:951-1002.
6. Braga, P. C. 1991. Interaction of antibiotics on enteric microflora, p. 509-517. In P. C. Braga, M. Guslandi, and A. Tittobello (ed.), Drugs in gastroenterology, Raven Press Ltd., New York, NY.
7. Brunner, M., et al. 2003. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment. Pharmacol. Ther. 17:395-402.
8. Brunner, M., et al. 2006. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br. J. Clin. Pharmacol. 61:31-38.
9. Donskey, C. J. 2004. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin. Infect. Dis. 39:219-226.
10. DuPont, H. L., M. M. Cooperstock, M. L. Corrado, R. Fakety, and D. M. Murray. 1992. Evaluation of new anti-infective drugs for the treatment of acute infectious diarrhea. Infectious Diseases Society of America and the Food and Drug Administration. Clin. Infect. Dis. 15(Suppl. 1):S228-S235.
11. Ericsson, C. D., et al. 1983. Bicozamycin, a poorly absorbable antibiotic, effectively treats traveller's diarrhoea. Ann. Intern. Med. 98:20-25.
12. Fürész, S., G. Acocella, and R. Scotti. 1963. Experimental data for the use of rifamycin SV in biliary tract infections: in vitro activity against various pathogenic bacteria and bile concentrations in man. Chemotherapy 12:365-373.
13. ICH. 2000. Harmonised tripartite guideline. Non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals M3(R1), recommended for adoption at step 4 of the ICH process on 16 July 1997 and amended on 9 November 2000 by the ICH Steering Committee. ICH, Geneva, Switzerland.
14. Jiang, Z. D., S. Ke, E. Palazzini, L. Riopel, and H. DuPont. 2000. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob. Agents Chemother. 44:2205-2206.
15. Maggi, N., A. Vigevani, and R. Pallanza. 1968. Desacetyl-rifamycins: preparation and antibacterial properties. Experientia 24:209-211.
16. Marchi, E., G. Mascellani, L. Montecchi, M. Burfani, and L. Cellai. 1983. L/105, a new semisynthetic derivative of ryfamicin SV, synthesis and structure-activity relationship. G. Ital. Chemioter. 2(Suppl. 5):38-50.
17. McFarland, L. V. 2000. Normal flora: diversity and functions. Microb. Ecol. Health Dis. 12:193-207.
18. McFarland, L. V. 2005. Alternative treatments for Clostridium difficile disease: what really works? J. Med. Microbiol. 54:101-111.
19. Salix Pharmaceuticals, Inc. 2007. Xifaxan® product leaflet, November 2007. Salix Pharmaceuticals, Inc., Morrisville, NC.
20. Sensi, P., M. T. Timbal, and G. Maffii. 1960. Rifomycin IX. Two new antibiotics of traveller family: traveller S and traveller SV. Preliminary report. Experientia 16:412.
21. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). June 2001. Guidance for industry. Bioanalytical methods validation. Department of Health and Human Services, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Washington, DC.
22. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). December 2002. Guidance for industry. Food-effect bioavailability and fed bio-equivalence studies. Department of Health and Human Services, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Washington, DC.
23. U.S. Department of Health and Human Services and U. S. Department of Agriculture. 2005. Nutrition and your health: dietary guidelines for Americans, 2005. U.S. Department of Health and Human Services and U. S. Department of Agriculture, Washington, DC. http://www.health.gov /dietaryguidelines/.
24. Viswanathan, C. T., et al. 2007. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24:1962-1973.